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Condensation 
Combined screening by maternal factors and biomarkers in the early third-trimester 
predicts nearly all cases of preterm preeclampsia and half of term preeclampsia. 
  
Short version of article title 
Third-trimester screening for preeclampsia  
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ABSTRACT 
 
BACKGROUND: Preeclampsia (PE) affects 2-3% of all pregnancies and is a major cause 
of maternal and perinatal morbidity and mortality. We have proposed a two-stage strategy 
for identification of pregnancies at high-risk of developing PE. The objective of the first 
stage, at 11-13 weeks’ gestation, is reduction in the prevalence of the disease through 
pharmacological intervention in the high-risk group. The objective of the second-stage, 
during the second and / or third trimesters, is to improve perinatal outcome through close 
monitoring of the high-risk group for earlier diagnosis of the clinical signs of the disease 
and selection of the appropriate, time, place and method of delivery. 
 
OBJECTIVE: To examine the performance of screening for PE by a combination of 
maternal factors with early third-trimester biomarkers. 
 
STUDY DESIGN: This was a cohort study and data were derived from consecutive 
women with singleton pregnancies attending for their routine hospital visit at 30-34 
weeks’ gestation in three maternity hospitals in England between March 2011 and 
December 2014. In the first phase of the study, only uterine artery pulsatility index (UTPI) 
was measured, then measurement of mean arterial pressure (MAP) was added and in the 
final phase serum concentration of placental growth factor (PLGF) was measured and 
then soluble fms-like tyrosine kinase-1 (SFLT) was added. We had data on UTPI, MAP, 
PLGF and SFLT from 30,935, 29,042, 10,123 and 8,264 pregnancies, respectively. Bayes 
theorem was used to combine the a priori risk from maternal factors with various 
combinations of biomarker multiple of the median (MoM) values. Ten-fold cross validation 
was used to estimate the performance of screening for PE requiring delivery at <37 
weeks’ gestation (preterm-PE) and those delivering at >37 weeks (term-PE). The 
empirical performance was compared to model predictions. 
 
RESULTS: In pregnancies that developed PE, the values of MAP, UTPI and SFLT were 
increased and PLGF was decreased. For all biomarkers the deviation from normal was 
greater for preterm-PE than term-PE and therefore the performance of screening was 
inversely related to the gestational age at which delivery become necessary for maternal 
and or fetal indications. Combined screening by maternal factors, MAP, UTPI, PLGF and 
SFLT predicted 98% (95% confidence interval 88 to 100%) of preterm-PE and 49% (95% 
confidence interval 42 to 57%) of term-PE, at false positive rate (FPR) of 5%. These 
empirical detection rates are compatible with the respective model-based rates of 98% 
and 54%, but the latter were optimistically biased. 
 
CONCLUSION: Combination of maternal factors and biomarkers in the early 
third-trimester could predict nearly all cases of preterm-PE and half of those with term-PE, 
at 5% FPR. 
 
 
Key words: Third trimester screening, Preeclampsia, Pyramid of pregnancy care, 
Survival model, Bayes theorem, Uterine artery Doppler, Mean arterial pressure, Placental 
growth factor, Soluble fms-like tyrosine kinase-1. 
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INTRODUCTION 
 
Preeclampsia (PE) affects 2-3% of all pregnancies and is a major cause of maternal and 
perinatal morbidity and mortality1,2. The objectives of screening for PE are firstly, to reduce 
the prevalence of the disease through pharmacological intervention in the high-risk group 
identified in the first-trimester of pregnancy3,4 and secondly, to minimize adverse perinatal 
events for those that develop PE by determining the appropriate time and place for 
delivery5. The second objective can be potentially achieved through screening in the 
second and / or the third-trimester of pregnancy. 
 
The traditional approach to screening for PE is to use a risk-scoring system based on 
maternal demographic characteristics and medical history (maternal factors)6,7. However, 
the performance of such approach, which essentially treats each risk factor as a separate 
screening test with additive detection rate (DR) and screen positive rate, is poor8-10. 
Similarly, studies have investigated the potential value of biomarkers in predicting PE by 
examining the proportion of affected and unaffected pregnancies exceeding a cut-off in 
the measurement of such biomarkers 11-17. An alternative approach to screening, which 
allows estimation of individual patient-specific risks of PE is to use Bayes theorem to 
combine the a priori risk from maternal factors, derived by a multivariable logistic model, 
with the results of various combinations of biophysical and biochemical markers 8-10. 
However, the measured levels of biomarkers depend on variables from maternal 
characteristics and medical history and for their effective use in risk assessment and 
screening these covariates need to be taken into account; this can be achieved by 
standardising biomarker levels into multiples of the normal median (MoM) values 18-21. 
 
We have previously reported that first-trimester screening by a combination of maternal 
factors with MoM values of mean arterial pressure (MAP), uterine artery pulsatility index 
(UTPI) and serum placental growth factor (PLGF) could predict 65% of preterm-PE and 
33% of term-PE, at 5% false positive rate (FPR) 9. Screening at 19-24 weeks by maternal 
factors, MAP, UTPI and PLGF improved the DR of preterm-PE to about 75%, but the DR 
of term-PE remained at 33% 10. There is some evidence that the prediction of both 
preterm-PE and term-PE is improved by screening in the early third-trimester than at 
19-24 weeks. We have previously reported on the development of a model of screening 
for PE by a combination of MAP, UTPI, PLGF and serum soluble fms-like tyrosine 
kinase-1 (SFLT) at 32 weeks, but the performance of screening was assessed by 
simulating from the fitted model and such approach is generally optimistically biased 
because it ignores errors of estimation and departures from the assumed model 22. 
 
The objective of this study of singleton pregnancies with data on MAP, UTPI, PLGF and 
SFLT at 30-34 weeks’ gestation is to examine the potential improvement in performance 
of screening by maternal factors alone with the addition of each biomarker and 
combinations of biomarkers. In the estimates of performance of screening, empirical 
results are compared to model-based rates.  
 
 
METHODS 
 
Study design and participants 
 
This was a cohort study and data were derived from consecutive women with singleton 
pregnancies during their routine hospital visit at 30+0 - 34+6 weeks’ gestation in three 
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maternity hospitals in England (King’s College Hospital between March 2011 and 
December 2014, University College London Hospital between December 2011 and 
November 2013 and Medway Maritime Hospital between November 2011 and August 
2014). In the first phase of the study, only UTPI was measured, then measurement of 
MAP was added and in the final phase serum concentration of PLGF was measured and 
then SFLT was added. The inclusion criteria, which were the same throughout the study, 
were singleton pregnancy delivering a non-malformed live birth or stillbirth at >24 weeks’ 
gestation. We excluded pregnancies with aneuploidies and major fetal abnormalities and 
those ending in termination, miscarriage or fetal death at <24 weeks. 
 
The left and right UTPI were measured by transabdominal color Doppler ultrasound and 
the mean PI was calculated 23. Measurements of MAP were obtained by validated 
automated devices and a standardized protocol 24. Measurement of serum concentration 
of PLGF and SFLT were by an automated biochemical analyzer within 10 minutes of 
blood sampling (Cobas e411 system, Roche Diagnostics, Penzberg, Germany). The 
inter-assay coefficients of variation for low and high concentrations were 5.4% and 3.0% 
for PlGF, and 3.0% and 3.2% for SFLT, respectively. Gestational age was determined 
from measurement of fetal crown-rump length (CRL) at 11-13 weeks or the fetal head 
circumference at 19-24 weeks 25,26. The women gave written informed consent to 
participate in the study, which was approved by the NHS Research Ethics Committee. 
 
Outcome measures 
 
Data on pregnancy outcome were collected from the hospital maternity records or the 
general medical practitioners of the women. The obstetric records of all women with 
pre-existing or pregnancy associated hypertension were examined to determine if the 
condition was PE or pregnancy induced hypertension (PIH), as defined by the 
International Society for the Study of Hypertension in Pregnancy 27. Outcome measures 
were PE delivering at <37 weeks’ gestation (preterm-PE) and at >37 weeks (term-PE). 
The unaffected group contained all pregnancies without PE or PIH. 
 
Statistical analyses 
 
Performance of screening was assessed firstly, by examining the empirical results in 
7,927 pregnancies with complete data on MAP, UTPI, PLGF and SFLT, secondly, by 
examining the empirical results using all available data for each biomarker and thirdly, by 
modeling, whereby values on biomarkers were simulated for our 123,406 singleton 
pregnancies with available data on maternal factors 10. In selecting the second option, we 
wanted to have the maximum possible data for developing the models and examining 
performance of the various biomarkers; for example, in examining UTPI we could use 
data from 30,935 pregnancies, rather than just 7,927. However, the distribution of 
maternal factors was not identical in each subset used for assessment of each biomarker 
or their combinations; consequently, there were differences between the datasets in the 
maternal factor related performance of screening and it was therefore difficult to compare 
meaningfully the additional contribution to performance between biomarkers and their 
combinations over and above that of maternal factors alone. To overcome this problem 
we obtained modeled estimates of performance by sampling biomarker multiple of the 
normal median (MoM) values from the fitted multivariate log Gaussian distribution in the 
large dataset of 123,406 pregnancies.   
 
Competing risks model 
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This model assumes that if the pregnancy was to continue indefinitely all women would 
develop PE and whether they do so or not before a specified gestational age depends on 
competition between delivery for PE or for other reasons 28. The effect of each maternal 
factor is to modify the mean of the distribution of gestational age at delivery with PE so 
that in pregnancies at low-risk for PE the gestational age distribution is shifted to the right 
with the implication that in most pregnancies delivery will actually occur for other reasons 
before development of PE. In high-risk pregnancies, the distribution is shifted to the left 
and the smaller the mean gestational age the higher is the risk for PE. The distribution of 
biomarkers is specified conditionally on the gestational age at delivery with PE. For any 
women with specific maternal factors and biomarker MoM, the posterior distribution of the 
time to delivery with PE is obtained from the application of Bayes theorem.   
 
Gestational age at delivery with PE was defined by two components: firstly, the prior 
distribution based on maternal factors 8 and secondly, the conditional distribution of MoM 
biomarker values given the gestational age with PE and maternal factors. Values of MAP, 
UTPI, PLGF and SFLT were expressed as MoMs adjusting for those characteristics found 
to provide a substantive contribution to their values, including the maternal factors in the 
prior model 18-21. In the PE group, the mean log10 MoM was assumed to depend linearly 
with gesational age at delivery and this linear relationship was assumed to continue until 
the mean log10 MoM of zero, beyond which the mean was taken as zero; this assumption 
was confirmed by the empirical results shown in Figure 1. Multivariable Gaussian 
distributions were fitted to the log10 MoM values of the biomarkers and a common 
covariance matrix was assumed for these distributions. Analysis of residuals was used to 
check the adequacy of the model and assess the effects of maternal factors on log10 
transformed MoM values in pregnancies with PE. 
 
Empirical performance of screening  
 
Ten-fold cross validation was used to assess the empirical performance of screening for 
PE by maternal factors and the combination of maternal factors with biomarkers. The 
data were divided into 10 equal subgroups, the model was then fitted 10 times to different 
combinations of nine of the 10 subgroups and used to predict risk of PE in the remaining 
tenth of the data. In each case, the maternal factor model, the regression models, and the 
covariance matrix were fitted to the training data set comprising nine tenths on the data 
and used to produce risks for the hold out sample comprising the remaining tenth of the 
data. The positive and negative likelihood ratios  
 
Model-based estimates of screening performance 
 
To provide model-based estimates of screening performance, the following procedure 
was adopted. First, we obtained the dataset of 123,406 singleton pregnancies, including 
2,748 (2.2%) with PE, that was previously used to develop a model for PE based on 
maternal demographic characteristics and medical history 8. Second, for each case of PE 
(n=2,748) and pregnancies unaffected by PE or PIH (n=117,710), the biophysical and 
biochemical MoM values were simulated from the fitted multivariate Gaussian distribution 
for log transformed MoM values. Third, risks were obtained using the competing risk 
model from the simulated MoM values and the pregnancy characteristics. These three 
steps were applied to the pregnancies within the unaffected group with no restriction on 
the time of delivery. Fourth, for a given FPR, risks from the unaffected group were used to 
define a risk cut-off. The proportion of PE risks was then used to obtain an estimate of the 
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associated DR. The area under the receiver operating characteristic curve (AUROC) was 
also calculated. The simulations were repeated 100 times to reduce variability due to the 
simulation process and provide suitably precise model-based estimates of performance. 
 
Performance of biomarkers without adjustment for maternal factors. 
 
The 90th and 95th percentiles for UTPI, MAP and SFLT and the 10th and 5th percentiles for 
PLGF were derived from the measurements of these biomarkers in unaffected 
pregnancies without conversion to MoM values. The performance of screening for PE 
was estimated using these percentile cut-offs. 
 
The statistical software package R was used for data analyses 29. The survival package 30 
was used for fitting the maternal factors model and the package pROC 31 was used for 
the receiver operating characteristic (ROC) curve analysis.   
 
 
RESULTS 
 
Characteristics of the study population  
 
The characteristics of the pregnancies with data on MAP, UTPI, PLGF and SFLT are 
given in Table S1, those of the 7,927 pregnancies with complete data on UTPI, MAP, 
PLGF and SFLT are given in Table S2 and those of the total population of 123,406 
pregnancies with maternal factors are given in Table S3. 
 
Distribution of biomarkers  
 
The distributions of log10 MoM values of the biomarkers in unaffected pregnancies and in 
those that developed PE are shown in Tables S4 and S5. In the unaffected group, the 
median MoM value is 1.0 and on the log scale the distribution of MoM values is very well 
approximated by a Gaussian distribution with mean zero. The MoM values in the PE 
group and the fitted regression relationships with gestational age at delivery are shown in 
Figure 1. All markers showed more separation at earlier than later gestations and this is 
reflected in their superior performance at detection of preterm-PE than term-PE. 
 
The distribution of measurements of biomarkers without adjustment for maternal factors 
is shown in Figure S1. The 90th and 95th percentiles for MAP were 96.9 and 100.0 mmHg, 
and the respective values for UTPI were 1.03 and 1.17 and for SFLT were 3,187 and 
3,887 pg/mL. The 10th and 5th percentiles for PLGF were 206.3 and 150.6 pg/mL, 
respectively. 
 
Performance of screening for preeclampsia 
 
Empirical and model-based performance of screening for PE by maternal factors and 
combinations of biomarkers are shown in Tables 1-3, S6 and Figures 2 and 3. The 
empirical performance of screening of all available data (Table 1) is compatible with the 
performance in the 7,927 pregnancies with complete data (Table S6), but in the latter the 
confidence intervals are wider because of fewer data. The empirical DRs are also 
compatible with the model-based rates, but the latter are optimistically biased (Table 1). 
Table 2 provides the positive and negative LRs for preterm-PE and term-PE. The AUROC 
curves for prediction of PE and model-based results are shown in Table 3. Figure 2 
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shows the ROC curves for empirical prediction of PE by maternal factors, combination of 
maternal factors with each biomarker and all biomarkers. Figure 3 shows the empirical 
performance of screening for PE by combination of maternal factors with all available 
data on biomarkers; the empirical results are compatible with the model-based results. 
 
The performance of screening for preterm-PE and term-PE by individual biomarkers 
using percentile cut-offs from unadjusted measurements, compared to our approach of 
combining the prior risk from maternal factors with biomarker MoM values is shown in 
Table 4; in general, the DR from combined screening was higher, particularly for term-PE.  
 
 
COMMENT 
 
Principal findings of this study 
 
In pregnancies that develop PE, the early third-trimester values of UTPI, MAP and SFLT 
are increased and PLGF is decreased. For all biomarkers the deviation from normal is 
inversely related to the gestational age at which delivery becomes necessary for maternal 
and or fetal indications and therefore, the performance of screening is better for 
preterm-PE than term-PE.  
 
The performance of screening achieved by maternal factors is improved by the addition 
of MAP, UTPI, PLGF or SFLT. Although the study provides some evidence on the 
potential value of various combinations of biomarkers, it was not powered to demonstrate 
significant improvement in performance with the addition of one or more biomarkers to 
that achieved by a combination of maternal factors with any one of the biomarkers. 
 
Screening for PE by a combination of maternal factors, MAP, UTPI, PLGF and SFLT at 
30-34 weeks’ gestation could predict, at 5% FPR, 98% of preterm-PE and 49% of 
term-PE. Consequently, the performance of screening at 30-34 weeks is superior to that 
achieved by screening at 11-13 or 19-24 weeks with respective DRs of about 65% and 
75% for preterm-PE and 33% for term-PE 9,10. In screening by all biomarkers, a screen 
positive result at 5% FPR, is associated with a 20-fold increase in odds ratio for 
preterm-PE and 11-fold increase for term-PE; a screen negative result is associated with 
a 42-fold decrease in odds ratio for preterm-PE and 2-fold decrease for term-PE. 
 
The traditional approach to screening for PE is to use individual factors from maternal 
characteristics and obstetric history or the results of individual biomarker percentile 
cut-offs to define the screen positive group. This is analogous to screening for Down 
syndrome by individual cut-offs in maternal age, first-trimester fetal nuchal translucency 
thickness, serum PAPP-A or free ß-hCG. Our proposed approach to screening for PE, 
which utilizes Bayes theorem to combine maternal factors with multiple biomarkers, has a 
performance which is superior to that achieved with screening by maternal factors alone 
or individual biomarkers alone. We found that at 5% FPR, the DR of preterm-PE in 
screening by our approach using all four biomarkers was 98% (95% CI 88-100%), 
compared to 81% in screening with SFLT, which was the best of the individual biomarkers. 
This concept is now well accepted in screening for Down syndrome where a combined 
risk cut-off, rather than individual biomarker cut-offs, is used to guide pregnancy 
management and there is no reason to believe that the same philosophy could not be 
adopted in screening for PE and other pregnancy complications. The software for such 
estimation of combined risk for PE is freely available (website Am JOG).    
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Strengths and limitations 
 
The strengths of this early third-trimester screening study for PE are first, examination of 
a large population of pregnant women attending for routine care in a gestational age 
range which is widely used for assessment of fetal growth and wellbeing, second, 
recording of data on maternal characteristics and medical history to define the prior risk, 
third, use of a specific methodology and appropriately trained doctors to measure MAP 
and UTPI, fourth, use of automated machines to provide accurate measurement within 40 
minutes of sampling of maternal serum concentration of PLGF and SFLT, fifth, expression 
of the values of the biomarkers as MoMs after adjustment for factors that affect the 
measurements, and sixth, use of Bayes theorem to combine the prior risk from maternal 
factors with biomarkers to estimate patient-specific risks and the performance of 
screening for PE delivering at different stages of pregnancy. 
 
A limitation of the study is that some of the findings rely on modeling which introduces 
optimistic bias. We have used 10-fold cross validation on the empirical data which 
reduces such bias and demonstrated that the performance was compatible with that 
derived from modeling. 
 
Comparison with previous studies 
 
Previous studies examining biomarkers in the late second or early third trimesters of 
pregnancy have essentially focused on the investigation of women presenting to 
specialist clinics with signs of hypertensive disorders with the aim of identifying the 
subgroup that will develop severe disease 11-17,32. Our study examined the application of 
biomarkers in routine screening for subsequent development of PE as part of a strategy 
for a new approach to prenatal care 33. 
 
Clinical implications of the study 
 
In the traditional approach to prenatal care, screening and diagnosis of PE is based on 
the demonstration of elevated blood pressure and proteinuria during a routine clinical visit 
in the late second- or third-trimester of pregnancy. In a proposed new pyramid of 
pregnancy care 33, the timing and content of clinical visits should be defined by the 
patient-specific risk of developing PE; the objective would be to minimize adverse 
perinatal events for those that develop PE by determining the appropriate time and place 
for delivery. 
 
Stratification of risk for PE can be achieved by a combination of maternal factors and 
biomarkers, but there is an inherent contradiction in selecting the best time for such 
assessment. The incidence of PE increases with gestational age; in our study population 
of 123,406 singleton pregnancies, there were 2,748 cases of PE and the gestational age 
at delivery of the PE group was <32 weeks in 9% of cases, 32+0 - 36+6 weeks in 20% and 
>37 weeks in 71%. In contrast, the incidence of adverse fetal and maternal short-term 
and long-term consequences of PE is inversely related to the gestational age at onset of 
the disease 34-39. Similarly, the performance of screening for PE at any gestational age is 
inversely related to the gestational age at delivery with PE. Screening at around 22 weeks’ 
gestation could identify, at 5% FPR, all cases of early-PE requiring delivery at <32 weeks, 
but only 65% of PE at 32+0 - 36+6 weeks and 33% of PE at >37 weeks 10. The present 
study has shown that screening at around 32 weeks’ gestation could identify, at 5% FPR, 
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98% of cases of PE requiring delivery at 32+0 - 36+6 weeks, but only 49% of PE at >37 
weeks. In another screening study at around 36 weeks’ gestation, we found that about 
85% of cases of PE at >37 weeks could be identified at 10% FPR 40. 
 
Future studies will firstly, define contingent strategies for appropriate selection of patients 
that would benefit from assessment at 22, 32 and / or 36 weeks’ gestation, secondly, 
develop management protocols for the high-risk pregnancies identified at such visits and 
thirdly, examine whether the implementation of such protocols could improve perinatal 
outcome. 
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Figure legends 
 
Figure 1. Scatter diagram and regression line for the relationship between uterine artery 
pulsatility index, mean arterial pressure, serum placental growth factor and soluble 
fms-like tyrosine kinase-1 multiple of the median (MoM) and gestational age at delivery in 
pregnancies with preeclampsia. 
 
Figure 2. Receiver operating characteristic curves for prediction of preeclampsia at <37 
weeks’ gestation (left) and at >37 weeks (right) by maternal factors (black) and 
combination of maternal factors with uterine artery pulsatility index (blue), mean arterial 
pressure (green), serum placental growth factor (purple), soluble fms-like tyrosine 
kinase-1 (red) and combination of maternal factors with all biomarkers (bold black).  
 
Figure 3. Empirical detection rates of preeclampsia at <37 weeks (red lines and circles) 
and at >37 weeks (black lines and circles), with 95% confidence interval, in screening by 
combination of maternal factors with uterine artery pulsatility index, mean arterial 
pressure, serum placental growth factor and soluble fms-like tyrosine kinase-1. The open 
circles represent the model-based detection rates. 
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Table 1. Empirical performance of screening for preeclampsia with delivery at <37 and >37 weeks’ gestation from all available data. 
The numbers in bold in each cell are the detection rates obtained from modeling. 
Method of screening 
Preeclampsia at <37 weeks Preeclampsia at >37 weeks 
History Combined History Combined 
n/N DR % (95% CI) n/N DR % (95% CI) n/N DR % (95% CI) n/N DR % (95% CI) 
False positive rate 5% 
 
 
 
 
 
 
 
 
Maternal factors 61/179 34 (27, 42) 61/179 34 (27 ,42); 34 169/555 30 (27, 34) 169/555 30 (27, 34); 27 
MAP 42/136 31 (23, 39) 98/136 72 (64 ,79); 79 148/509 29 (25, 33) 197/509 39 (34, 43); 36 
UTPI 55/166 33 (26, 41) 105/166 63 (55 ,71); 70 165/540 31 (27, 35) 172/540 32 (28, 36); 27 
PLGF 16/56 29 (17, 42) 44/56 79 (66 ,88); 86 64/240 27 (21, 33) 95/240 40 (33, 46); 41 
SFLT 13/47 28 (16, 43) 39/47 83 (69 ,92); 91 57/196 29 (23, 36) 75/196 38 (31, 45); 40 
MAP, UTPI 36/126 29 (21, 37) 100/126 79 (71 ,86); 88 144/495 29 (25, 33) 197/495 40 (35, 44); 37 
MAP, PLGF 16/54 30 (18, 44) 50/54 93 (82 ,98); 93 62/238 26 (21, 32) 110/238 46 (40, 53); 47 
MAP, SFLT 13/45 29 (16, 44) 41/45 91 (79 ,98); 95 56/194 29 (23, 36) 88/194 45 (38, 53); 47 
UTPI, PLGF 15/52 29 (17, 43) 43/52 83 (70 ,92); 91 62/236 26 (21, 32) 97/236 41 (35, 48); 42 
UTPI, SFLT 13/44 30 (17, 45) 38/44 86 (73 ,95); 94 55/192 29 (22, 36) 74/192 39 (32, 46); 41 
PLGF, SFLT 13/47 28 (16, 43) 43/47 91 (80 ,98); 96 57/196 29 (23, 36) 99/196 51 (43, 58); 50 
MAP, UTPI, PLGF 15/52 29 (17, 43) 49/52 94 (84 ,99); 95 60/234 26 (20, 32) 110/234 47 (40, 54); 47 
MAP, UTPI, SFLT 13/44 30 (17, 45) 40/44 91 (78 ,97); 97 54/190 28 (22, 35) 86/190 45 (38, 53); 48 
MAP, PLGF, SFLT 13/45 29 (16, 44) 42/45 93 (82 ,99); 97 56/194 29 (23, 36) 104/194 54 (46, 61); 48 
UTPI, PLGF, SFLT 13/44 30 (17, 45) 40/44 91 (78 ,97); 97 55/192 29 (22, 36) 95/192 49 (42, 57); 50 
MAP, UTPI, PLGF, SFLT 13/44 30 (17, 45) 43/44 98 (88 ,99); 98 54/190 28 (22, 35) 104/190 55 (47, 62); 54 
False positive rate 10% 
        
Maternal factors 80/179 45 (37, 52) 80/179 45 (37 ,52); 47 228/555 41 (37, 45) 228/555 41 (37, 45); 37 
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DR = detection rate; CI = confidence interval; UTPI = uterine artery pulsatility index; MAP = mean arterial pressure; PLGF = placental growth factor; 
SFLT = soluble fms-like tyrosine kinase-1. 
 
MAP 59/136 43 (35, 52) 109/136 80 (72 ,86); 87 207/509 41 (36, 45) 266/509 52 (48, 57); 49 
UTPI 72/166 43 (36, 51) 127/166 77 (69 ,83); 79 224/540 41 (37, 46) 229/540 42 (38, 47); 39 
PLGF 22/56 39 (26, 53) 52/56 93 (83 ,98); 92 90/240 38 (31, 44) 124/240 52 (45, 58); 55 
SFLT 19/47 40 (26, 56) 44/47 94 (82 ,99); 95 75/196 38 (31, 45) 100/196 51 (44, 58); 53 
MAP, UTPI 51/126 40 (32, 50) 106/126 84 (77 ,90); 93 202/495 41 (36, 45) 267/495 54 (49, 58); 50 
MAP, PLGF 22/54 41 (28, 55) 52/54 96 (87 ,99); 96 88/238 37 (31, 43) 144/238 61 (54, 67); 60 
MAP, SFLT 19/45 42 (28, 58) 42/45 93 (82 ,99); 98 73/194 38 (31, 45) 114/194 59 (51, 66); 59 
UTPI, PLGF 20/52 38 (25, 53) 47/52 90 (79 ,97); 95 88/236 37 (31, 44) 129/236 55 (48, 61); 55 
UTPI, SFLT 18/44 41 (26, 57) 41/44 93 (81 ,99); 97 75/192 39 (32, 46) 102/192 53 (46, 60); 54 
PLGF, SFLT 19/47 40 (26, 56) 47/47 100 (92,100); 98 75/196 38 (31, 45) 123/196 63 (56, 70); 62 
MAP, UTPI, PLGF 20/52 38 (25, 53) 50/52 96 (87 ,100); 97 86/234 37 (31, 43) 142/234 61 (54, 67); 60 
MAP, UTPI, SFLT 18/44 41 (26, 57) 43/44 98 (88 ,99); 99 72/190 38 (31, 45) 115/190 61 (53, 68); 60 
MAP, PLGF, SFLT 19/45 42 (28, 58) 44/45 98 (88 ,99); 99 73/194 38 (31, 45) 129/194 66 (59, 73); 60 
UTPI, PLGF, SFLT 18/44 41 (26, 57) 43/44 98 (88 ,99); 99 75/192 39 (32, 46) 118/192 61 (54, 68); 62 
MAP, UTPI, PLGF, SFLT 18/44 41 (26, 57) 43/44 98 (88 ,99); 99 72/190 38 (31, 45) 124/190 65 (58, 72); 66 
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Table 2. Positive and negative likelihood ratios for preeclampsia with delivery at <37 and >37 weeks’ gestation from all available data.  
Method of screening 
Preeclampsia at <37 weeks Preeclampsia at >37 weeks 
LR+ve (95% CI) LR –ve (95% CI) LR+ve (95% CI)* LR –ve (95% CI)* 
False positive rate 5% 
  
  
Maternal factors 6.8 (5.6, 8.4) 1.4 (1.3, 1.6) 6.1 (5.4, 6.9) 1.4 (1.3, 1.4) 
MAP 14.4 (12.8, 16.2) 3.4 (2.6, 4.5) 7.7 (6.9, 8.7) 1.5 (1.4, 1.7) 
UTPI 12.7 (11.2, 14.3) 2.6 (2.1, 3.2) 6.4 (5.6, 7.3) 1.4 (1.3, 1.5) 
PLGF 15.7 (13.4, 18.5) 4.4 (2.7, 7.3) 7.9 (6.6, 9.5) 1.6 (1.4, 1.7) 
SFLT 16.6 (14.1, 19.5) 5.6 (3.0, 10.5) 7.7 (6.2, 9.4) 1.5 (1.4, 1.7) 
MAP, UTPI 15.9 (14.3, 17.6) 4.6 (3.3, 6.5) 8.0 (7.1, 9.0) 1.6 (1.5, 1.7) 
MAP, PLGF 18.5 (16.5, 20.8) 12.8 (5.0, 32.9) 9.2 (7.8, 10.9) 1.8 (1.6, 2.0) 
MAP, SFLT 18.2 (16, 20.8) 10.7 (4.2, 27.2) 9.1 (7.6, 10.9) 1.7 (1.5, 2.0) 
UTPI, PLGF 16.5 (14.2, 19.2) 5.5 (3.0, 9.9) 8.2 (6.9, 9.8) 1.6 (1.4, 1.8) 
UTPI, SFLT 17.3 (14.8, 20.1) 7.0 (3.3, 14.7) 7.7 (6.3, 9.5) 1.5 (1.4, 1.7) 
PLGF, SFLT 18.3 (16.1, 20.8) 11.2 (4.4, 28.5) 10.1 (8.5, 12) 1.9 (1.7, 2.2) 
MAP, UTPI, PLGF 18.8 (16.9, 21.1) 16.5 (5.5, 49.4) 9.4 (8.0, 11.1) 1.8 (1.6, 2.0) 
MAP, UTPI, SFLT 18.2 (15.9, 20.8) 10.4 (4.1, 26.6) 9.1 (7.5, 10.9) 1.7 (1.5, 2.0) 
MAP, PLGF, SFLT 18.7 (16.5, 21.1) 14.2 (4.8, 42.5) 10.7 (9.1, 12.6) 2.0 (1.8, 2.4) 
UTPI, PLGF, SFLT 18.2 (15.9, 20.8) 10.4 (4.1, 26.6) 9.9 (8.3, 11.8) 1.9 (1.6, 2.2) 
MAP, UTPI, PLGF, SFLT 19.5 (17.6, 21.8) 41.8 (6.0, 290.2) 10.9 (9.3, 12.9) 2.1 (1.8, 2.5) 
False positive rate 10% 
    
Maternal factors 4.5 (3.8, 5.3) 1.6 (1.4, 1.9) 4.1 (3.7, 4.5) 1.5 (1.4, 1.6) 
MAP 8.0 (7.3, 8.8) 4.5 (3.2, 6.4) 5.2 (4.8, 5.7) 1.9 (1.7, 2.1) 
UTPI 7.7 (7.0, 8.4) 3.8 (2.9, 5.0) 4.2 (3.8, 4.7) 1.6 (1.5, 1.7) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LR = likelihood ratio; CI = confidence interval; UTPI = uterine artery pulsatility index; MAP = mean arterial pressure; PLGF = placental growth factor; 
SFLT = soluble fms-like tyrosine kinase-1. * the odds ratio for PE is increased by the positive LR and decreased by the negative LR 
 
PLGF 9.3 (8.5, 10.2) 12.6 (4.9, 32.4) 5.2 (4.5, 5.9) 1.9 (1.6, 2.1) 
SFLT 9.4 (8.5, 10.3) 14.1 (4.7, 42.1) 5.1 (4.4, 5.9) 1.8 (1.6, 2.1) 
MAP, UTPI 8.4 (7.7, 9.1) 5.7 (3.8, 8.5) 5.4 (4.9, 5.9) 2.0 (1.8, 2.1) 
MAP, PLGF 9.6 (8.9, 10.4) 24.3 (6.2, 94.7) 6.1 (5.4, 6.8) 2.3 (1.9, 2.7) 
MAP, SFLT 9.3 (8.4, 10.3) 13.5 (4.5, 40.3) 5.9 (5.1, 6.7) 2.2 (1.8, 2.6) 
UTPI, PLGF 9.0 (8.1, 10.1) 9.4 (4.1, 21.5) 5.5 (4.8, 6.2) 2.0 (1.7, 2.3) 
UTPI, SFLT 9.3 (8.4, 10.3) 13.2 (4.4, 39.4) 5.3 (4.6, 6.2) 1.9 (1.7, 2.2) 
PLGF, SFLT 10 (9.4, 10.7) ∞ (5.4, ∞) 6.3 (5.5, 7.1) 2.4 (2.0, 2.9) 
MAP, UTPI, PLGF 9.6 (8.9, 10.4) 23.4 (6.0, 91.1) 6.1 (5.4, 6.8) 2.3 (2.0, 2.7) 
MAP, UTPI, SFLT 9.5 (8.7, 10.5) 19.8 (5.1, 76.7) 5.9 (5.2, 6.8) 2.2 (1.9, 2.6) 
MAP, PLGF, SFLT 9.8 (9, 10.6) 40.5 (5.8, 281.3) 6.6 (5.9, 7.5) 2.7 (2.2, 3.3) 
UTPI, PLGF, SFLT 9.8 (9, 10.6) 39.6 (5.7, 274.9) 6.1 (5.4, 7.0) 2.3 (2.0, 2.8) 
MAP, UTPI, PLGF, SFLT 9.8 (9, 10.6) 39.6 (5.7, 274.9) 6.5 (5.8, 7.4) 2.6 (2.1, 3.1) 
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Table 3. Areas under the receiver operating characteristic curve of empirical results and 
model-based results in screening for preeclampsia by maternal factors and combination 
of maternal factors and biomarkers.  
 
 
PE = preeclampsia; CI = confidence interval; UTPI = uterine artery pulsatility index; MAP = mean 
arterial pressure; PLGF = placental growth factor; SFLT = soluble fms-like tyrosine kinase-1. 
Method of screening 
Areas under the receiver operating characteristic curve 
PE <37 w PE >37 w 
Empirical (95% CI) Model Empirical (95% CI) Model 
Maternal factors 0.784 (0.751, 0.817) 0.796 0.750 (0.729, 0.771) 0.752 
MAP 0.927 (0.906, 0.949) 0.954 0.812 (0.793, 0.832) 0.809 
UTPI 0.896 (0.869, 0.924) 0.928 0.759 (0.738, 0.780) 0.759 
PLGF 0.967 (0.950, 0.983) 0.972 0.819 (0.791, 0.847) 0.834 
SFLT 0.970 (0.952, 0.988) 0.981 0.808 (0.776, 0.841) 0.825 
MAP, UTPI 0.945 (0.924, 0.966) 0.975 0.818 (0.798, 0.838) 0.812 
MAP, PLGF 0.984 (0.973, 0.995) 0.985 0.851 (0.826, 0.876) 0.854 
MAP, SFLT 0.980 (0.964, 0.997) 0.991 0.844 (0.813, 0.874) 0.851 
UTPI, PLGF 0.967 (0.946, 0.988) 0.981 0.819 (0.791, 0.847) 0.834 
UTPI, SFLT 0.976 (0.959, 0.993) 0.989 0.810 (0.777, 0.843) 0.828 
PLGF, SFLT 0.987 (0.980, 0.994) 0.992 0.848 (0.819, 0.878) 0.862 
MAP, UTPI, PLGF 0.981 (0.964, 0.997) 0.990 0.851 (0.826, 0.876) 0.854 
MAP, UTPI, SFLT 0.982 (0.964, 0.999) 0.994 0.844 (0.813, 0.874) 0.853 
MAP, PLGF, SFLT 0.990 (0.983, 0.997) 0.994 0.867 (0.839, 0.894) 0.853 
UTPI, PLGF, SFLT 0.988 (0.981, 0.995) 0.995 0.847 (0.817, 0.877) 0.862 
MAP, UTPI, PLGF, SFLT 0.990 (0.982, 0.998) 0.996 0.865 (0.838, 0.893) 0.875 
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Table 4. Empirical performance of screening for preeclampsia from all available data by 
individual biomarkers using percentile cut-offs from unadjusted measurements and by a 
combination of prior risk from maternal factors with biomarker MoM values. 
 
 
 
 
CI = confidence interval; UTPI = uterine artery pulsatility index; MAP = mean arterial pressure; 
PLGF = placental growth factor; SFLT = soluble fms-like tyrosine kinase-1. 
 
 
Method of screening Preeclampsia at <37 weeks Preeclampsia at >37 weeks 
False positive rate 5% n/N % (95% CI) n/N % (95% CI) 
MAP >95th percentile 89/136 65 (57, 73) 164/509 32 (28, 36) 
Maternal factors plus MAP MoM 98/136 72 (64 ,79) 197/509 39 (34, 43) 
UTPI >95th percentile 90/166 54 (46, 62) 75/540 14 (11, 17) 
Maternal factors plus UTPI MoM 105/166 63 (55 ,71) 172/540 32 (28, 36) 
PLGF <5th percentile 43/56 77 (64, 87) 59/240 25 (19, 31) 
Maternal factors plus PLGF MoM 44/56 79 (66 ,88) 95/240 40 (33, 46) 
SFLT >95th percentile 39/47 83 (69, 92) 50/196 26 (20, 32) 
Maternal factors plus SFLT MoM 39/47 83 (69 ,92) 75/196 38 (31, 45) 
False positive rate 10% 
    
MAP >90th percentile 107/136 79 (71, 85) 222/509 44 (39, 48) 
Maternal factors plus MAP MoM 109/136 80 (72 ,86) 266/509 52 (48, 57) 
UTPI >90th percentile 113/166 68 (60, 75) 75/540 14 (11, 17) 
Maternal factors plus UTPI MoM 127/166 77 (69 ,83) 229/540 42 (38, 47) 
PLGF <10th percentile 49/56 88 (76, 95) 99/540 41 (35, 48) 
Maternal factors plus PLGF MoM 52/56 93 (83 ,98) 124/240 52 (45, 58) 
SFLT >90th percentile 39/47 83 (69, 92) 50/196 26 (20, 32) 
Maternal factors plus SFLT MoM 44/47 94 (82 ,99) 100/196 51 (44, 58) 
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Table S1. Maternal and pregnancy characteristics in the screening population with data on biomarkers. 
 
Maternal factors 
Mean arterial pressure Uterine artery pulsatility index Serum PLGF Serum SFLT 
Unaffected 
(n=28,397) 
Preeclampsia 
(n=645) 
Unaffected 
(n=30,229) 
Preeclampsia 
(n=706) 
Unaffected 
(n=9,827) 
Preeclampsia 
(n=296) 
Unaffected 
(n=8,021) 
Preeclampsia 
(n=243) 
Maternal age in years, median (IQR) 31.3 (26.7, 35.0) 31.3 (26.5, 35.3) 31.3 (26.8, 35.0) 31.55 (26.925, 35.7) 31.1 (26.7, 34.8) 31.35 (26.95, 34.8) 30.9 (26.6, 34.7) 31.5 (27.0, 35.0) 
Maternal weight in kg, median (IQR) 75.3 (67.7, 85.5) 83.0 (72.0, 97.3)* 75.1 (67.5, 85.3) 82.9 (72.0, 97.2)* 76.5 (68.5, 87.0) 83.5 (72.0, 97.8)* 76.7 (68.5, 87.2) 84.5 (72.9, 98.5)* 
Maternal height in cm, median (IQR) 165 (160, 169) 164 (159, 168)* 165 (160, 169) 164 (160, 169) 165 (160, 169) 164 (159, 168)* 165 (160, 169) 164 (159, 168)* 
Body mass index, median (IQR) 27.8 (25.2, 31.4) 31.0 (27.3, 35.5)* 27.8 (25.1, 31.4) 30.7 (27.3, 35.4)* 28.1 (25.4, 31.9) 31.2 (27.5, 35.5)* 28.2 (25.3, 32.0) 31.3 (27.9, 35.7)* 
Gestational age in weeks, median (IQR) 32.3 (32.0, 32.9) 32.2 (32.0, 32.6)* 32.3 (32.0, 32.9) 32.2 (32.0, 32.7)* 32.2 (32.0, 32.5) 32.1 (32.0, 32.4) 32.2 (32.0, 32.5) 32.1 (32.0, 32.4) 
Racial origin 
 
* 
 
* 
 
* 
 
* 
  Caucasian, n (%) 19,903 (70.1) 352 (54.6) 21,255 (70.3) 383 (54.3) 7,207 (73.3) 171 (57.8) 6,044 (75.4) 148 (60.9) 
  Afro-Caribbean, n (%) 5,284 (18.6) 239 (37.1) 5,538 (18.3) 265 (37.5) 1,831 (18.6) 104 (35.1) 1,357 (16.9) 78 (32.1) 
  South Asian, n (%) 1,629 ( 5.7) 32 (5.0) 1,764 ( 5.8) 33 (4.7) 369 (3.8) 11 (3.7) 294 (3.7) 11 (4.5) 
  East Asian, n (%) 886 ( 3.1) 10 (1.6) 947 ( 3.1) 12 (1.7) 191 (1.9) 6 (2.0) 147 (1.8) 4 (1.7) 
  Mixed, n (%) 695 ( 2.5) 12 (1.9) 725 ( 2.4) 13 (1.8) 229 (2.3) 4 (1.4) 179 (2.2) 2 (0.8) 
Medical history 
        
  Chronic hypertension, n (%) 309 ( 1.1) 85 (13.2)* 353 (1.2) 104 (14.7)* 109 (1.1) 40 (13.5)* 94 (1.2) 34 (14.0)* 
  Diabetes mellitus, n (%) 273 ( 1.0) 19 (3.0)* 285 (0.9) 17 (2.4)* 97 (1.0) 4 (1.4) 75 (0.9) 3 (1.2) 
  SLE/APS, n (%) 53 ( 0.2) 0 (0.0) 57 (0.2) 1 (0.1) 16 (0.2) 0 (0.0) 15 (0.2) 0 (0.0) 
Conception 809 ( 2.9) 29 (4.5)* 847 (2.8) 35 (5.0)* 312 (3.2) 16 ( 5.4)* 231 (2.9) 10 (4.1) 
  Natural, n (%) 
        
  In vitro fertilization, n (%) 27,340 (96.3) 613 (95.0%) 29,084 (96.2) 671 (95.0) 9,507 (96.7) 283 (95.6) 7,757 (96.7) 233 (95.9) 
  Ovulation induction drugs, n (%) 754 ( 2.7) 24 (3.7%) 817 (2.7) 25 (3.5) 229 (2.3) 8 (2.7) 190 (2.4) 5 (2.1) 
Family history of preeclampsia, (n, %) 303 ( 1.1) 8 (1.2) 328 (1.1) 10 (1.4) 91 (0.9) 5 (1.7) 74 (0.9) 5 (2.1) 
Parity 
 
* 
 
* 
 
* 
 
* 
  Nulliparous, n (%) 13,931 (49.1) 395 (61.2) 14,850 (49.1) 425 (60.2) 4,758 (48.4) 172 (58.1) 3,899 (48.6) 142 (58.4) 
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  Parous with no previous PE, n (%) 13,712 (48.3) 176 (27.3) 14,546 (48.1) 192 (27.2) 4,749 (48.3) 84 (28.4) 3,860 (48.1) 64 (26.3) 
  Parous with previous PE, n (%) 754 (2.7) 74 (11.5) 833 (2.8) 89 (12.6) 320 (3.3) 40 (13.5) 262 (3.3) 37 (15.2) 
Inter-pregnancy interval in years, median (IQR) 3.0 (2.0, 4.9) 3.7 (2.4, 6.7)* 3.0 (2.0, 4.9) 3.7 (2.3, 6.8)* 3.1 (2.1, 5.2) 3.75 (2.4, 6.2)* 3.1 (2.1, 5.1) 4.1 (2.6, 6.2) 
Outcome: delivery at <37 w 1155 (4.0) 136 (21.1)* 1279 (4.2) 166 (23.5)* 430 (4.4%) 56 (19.0)* 359 (4.5) 47 (19.3)* 
   
Data provided as median (interquartile range) or n (%); PLGF = placental growth factor; SFLT= soluble fms-like tyrosine kinase-1; SLE = systemic 
lupus erythematosus; APS = antiphospholipid syndrome; PE = preeclampsia; Comparisons between outcome groups were by chi-square or Fisher 
exact test for categorical variables and Mann Whitney-U test for continuous variables; * significance value p<0.05 
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Table S2. Maternal and pregnancy characteristics in the population with complete data 
on all four biomarkers.  
 
Maternal factors Unaffected (n=7,693) 
Preeclampsia 
(n=234) 
PIH 
(n=201) 
Maternal age in years, median (IQR) 31.0 (26.6, 34.7) 31.5 (27.0, 34.9) 31.2 (27.5, 36.0) 
Maternal weight in kg, median (IQR) 76.7 (68.5, 87.1) 84.6 (72.4, 98.7)* 83.4 (74.5, 96.0)* 
Maternal height in cm, median (IQR) 165 (160, 169) 164 (159, 168) 165 (160, 170) 
Body mass index, median (IQR) 28.2 (25.4, 32.0) 31.3 (27.5, 35.7)* 30.7 (27.7, 34.8)* 
Gestational age in weeks, median (IQR) 32.2 (32.0, 32.5) 32.1 (32.0, 32.4)* 32.1 (32.0, 32.4) 
Racial origin 
 * * 
  Caucasian, n (%) 5,802 (75.4) 142 (60.7) 121 (60.2) 
  Afro-Caribbean, n (%) 1,293 (16.8) 76 (32.5) 60 (29.9) 
  South Asian, n (%) 286 (3.7) 10 (4.3) 11 (5.5) 
  East Asian, n (%) 142 (1.9) 4 (1.7) 3 (1.5) 
  Mixed, n (%) 170 (2.2) 2 (0.9) 6 (3.0) 
Medical history 
   
  Chronic hypertension, n (%) 90 (1.2) 32 (13.7)* 0 (0.0) 
  Diabetes mellitus, n (%) 73 (1.0) 3 (1.3) 4 (2.0) 
  SLE/APS, n (%) 15 (0.2) 0 (0.0) 0 (0.0) 
Conception 224 (2.9) 9 (3.9) 11 (5.5) 
  Natural, n (%) 
   
  In vitro fertilization, n (%) 7,438 (96.7) 225 (96.2) 193 (96.0) 
  Ovulation induction drugs, n (%) 184 (2.4) 5 (2.1) 5 (2.5) 
Family history of preeclampsia, (n, %) 71 (0.9) 4 (1.7) 3 (1.5) 
Parity 
 * * 
  Nulliparous, n (%) 3,747 (48.7) 136 (58.1) 124 (61.7) 
  Parous with no previous PE, n (%) 3,697 (48.1) 63 (26.9) 55 (27.4) 
  Parous with previous PE, n (%) 249 (3.2) 35 (15.0) 22 (11.0) 
Inter-pregnancy interval in years, median (IQR) 3.1 (2.1, 5.1) 4.1 (2.6, 6.3)* 3.4 (2.1, 6.1) 
Outcome: delivery at <37 w 341 (4.4) 44 (18.8)* 14 (7.0) 
   
Data provided as median (interquartile range) or n (%); PIH = pregnancy induced hypertension; 
SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome; PE = preeclampsia; 
Comparisons between outcome groups were by chi-square or Fisher exact test for categorical 
variables and Mann Whitney-U test for continuous variables; * significance value p<0.05 
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Table S3. Characteristics of the screening population with data on maternal factors.  
 
 
 
 
PE = preeclampsia; PIH = pregnancy induced hypertension; IQR = interquartile range; SLE = 
systemic lupus erythematosus; APS = antiphospholipid syndrome; Comparisons between with 
unaffected group were by chi-square or Fisher exact test for categorical variables and Mann 
Whitney-U test for continuous variables; * significance value p<0.05. 
Maternal factors Unaffected (n=117,710) Preeclampsia (n=2,748) PIH (n=2,948) 
Maternal age in years, median (IQR) 31.3 (26.7, 35.1) 31.4 (26.6, 36.0)*  31.8 (27.2, 35.5)* 
Maternal weight in kg, median (IQR) 75.2 (67.5, 85.3) 83.0 (72.0, 97.3)* 82.1 (73.5, 93.9)* 
Maternal height in cm, median (IQR) 164 (160, 169) 163 (158, 167)* 165 (160, 169) 
Body mass index, median (IQR) 27.8 (25.1, 31.4) 30.8 (27.3, 35.5)* 30.1 (27.2, 34.5)* 
Gestational age in weeks, median (IQR) 32.3 (32.0, 32.9) 32.2 (32.0, 32.7) 32.2 (32.0, 32.7) 
Racial origin 
 * * 
  Caucasian, n (%) 87,373 (74.2) 1,585 (57.7) 2,010 (68.2) 
  Afro-Caribbean, n (%) 18,313 (15.6) 907 (33.0) 668 (22.7) 
  South Asian, n (%) 6,120 (5.2) 153 (5.6) 148 (5.0) 
  East Asian, n (%) 3,106 (2.6) 47 (1.7) 53 (1.8) 
  Mixed, n (%) 2,798 (2.4) 56 (2.0) 69 (2.3) 
Medical history 
   
  Chronic hypertension, n (%) 1,198 (1.0) 288 (10.5)* 0 (0.0)* 
  Diabetes mellitus, n (%) 893 (0.8) 61 (2.2)* 35 (1.2)* 
  SLE/APS, n (%) 207 (0.2) 16 (0.6)* 9 (0.3) 
Conception 
 *  
  Natural, n (%) 113,530 (96.5) 2,595 (94.4) 2,823 (95.8) 
  In vitro fertilization, n (%) 2,632 (2.2) 111 ( 4.0) 83 (2.8) 
  Ovulation induction drugs, n (%) 1,548 (1.3) 42 (1.5) 42 (1.4) 
Family history of preeclampsia, (n, %) 4,243 (3.6) 201 (7.3)* 220 (7.5)* 
Parity 
   
  Nulliparous, n (%) 57,720 (49.0) 1,718 (62.5) 1,888 (64.0)* 
  Parous with no previous PE, n (%) 56,848 (48.3) 672 (24.5) 765 (26.0)* 
  Parous with previous PE, n (%) 3,142 (2.7) 358 (13.0) 295 (10.0)* 
Inter-pregnancy interval in years, median (IQR) 2.9 (1.9, 4.8) 3.9 (2.3, 6.8)* 3.4 (2.0, 5.7)* 
Outcome: delivery at <37 w 5,742 (4.9) 790 (28.7)* 209 (7.0)* 
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Table S4. Fitted regression models for marker log10 multiple of the median (MoM) values 
on gestation at time of delivery for pregnancies with preeclampsia. 
 
Biomarker Estimate (95% confidence interval) 
Uterine artery pulsatility index 
 
Intercept 0.58277005 (0.492569 to 0.672971) 
Slope 
-0.03711911 (-0.04302 to -0.03121) 
Mean arterial pressure 
 
Intercept 0.167589 (0.144884, 0.190295) 
Slope -0.009140 (-0.01085, -0.007430) 
Placental growth factor 
 
Intercept -1.81944 (-2.01496, -1.62392) 
Slope 0.09794 (0.083677, 0.112203) 
Soluble fms-like tyrosine kinase-1 
 
Intercept 1.391707 (1.126765, 1.656649) 
Slope 
-0.07865 (-0.09757, -0.05974) 
 
In the regression models, gestational age was centred at 24 weeks so the intercept represents the 
mean at 24 weeks.
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Table S5. Standard deviations and correlations, with 95% confidence limits, for log10 
multiples of the median biomarker values.  
 
 
 
Pooled refers to estimates obtained from pooling data for the preeclampsia and no preeclampsia 
groups. 
MAP = mean arterial pressure; UTPI = uterine artery pulsatility index; PLGF = placental growth 
factor; SFLT= soluble fms-like tyrosine kinase-1.
 
Unaffected Preeclampsia Pooled estimate 
Standard deviation 
 
  
MAP 29,157 645 0.03463 (0.03419, 0.03475) 
UTPI 31,035 706 0.11245 (0.11158, 0.11334) 
PLGF 10,104 296 0.31557 (0.31133, 0.31993) 
SFLT 8,229 243 0.19392 (0.19103, 0.1969) 
Correlations 
   
MAP and UTPI 28,622 621 0.00683 (-0.00454, 0.0182) 
MAP and PLGF 9,821 292 -0.15263 (-0.16371, -0.1415) 
MAP and SFLT 7,973 239 0.07838 (0.06707, 0.08967) 
UTPI and PLGF 9,977 288 -0.10196 (-0.11285, -0.09104) 
UTPI and SFLT 8,128 236 -0.02159 (-0.0326, -0.01057) 
PLGF and SFLT 8,229 243 -0.15609 (-0.17484, -0.13722) 
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Table S6. Empirical performance of screening for preeclampsia in the subgroup of 7,748 
pregnancies with complete data on all biomarkers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PE = preeclampsia; CI = confidence interval; MAP = mean arterial pressure; UTPI = uterine artery 
pulsatility index; PLGF = placental growth factor; SFLT = soluble fms-like tyrosine kinase-1. 
Method of screening 
PE at <37 w PE at >37 w 
n/N % (95% CI) n/N % (95% CI) 
False positive rate 5% 
 
 
 
 
Maternal factors 13/44 30 (17, 45) 54/190 28 (22, 35) 
MAP 33/44 75 (60, 87) 73/190 38 (31, 46) 
UTPI 29/44 66 (50, 80) 55/190 29 (23, 36) 
PLGF 35/44 80 (65, 90) 80/190 42 (35, 49) 
SFLT 37/44 84 (70, 93) 71/190 37 (30, 45) 
MAP, UTPI 36/44 82 (67, 92) 73/190 38 (31, 46) 
MAP, PLGF 41/44 93 (81, 99) 93/190 49 (42, 56) 
MAP, SFLT 40/44 91 (78, 97) 86/190 45 (38, 53) 
UTPI, PLGF 38/44 86 (73, 95) 81/190 43 (36, 50) 
UTPI, SFLT 38/44 86 (73, 95) 73/190 38 (31, 46) 
PLGF, SFLT 41/44 93 (81, 99) 94/190 49 (42, 57) 
MAP, UTPI, PLGF 41/44 93 (81, 99) 93/190 49 (42, 56) 
MAP, UTPI, SFLT 40/44 91 (78, 97) 86/190 45 (38, 53) 
MAP, PLGF, SFLT 42/44 93 (82, 99) 102/190 54 (46, 61) 
UTPI, PLGF, SFLT 40/44 91 (78, 97) 95/190 50 (43, 57) 
MAP, UTPI, PLGF, SFLT 43/44 98 (88, 99) 104/190 55 (47, 62) 
False positive rate 10% 
    
Maternal factors 18/44 41 (26, 57) 72/190 38 (31, 45) 
MAP 38/44 86 (73, 95) 100/190 53 (45, 60) 
UTPI 31/44 70 (55, 83) 72/190 38 (31, 45) 
PLGF 42/44 95 (85, 99) 102/190 54 (46, 61) 
SFLT 41/44 93 (81, 99) 96/190 51 (43, 58) 
MAP, UTPI 38/44 86 (73, 95) 101/190 53 (46, 60) 
MAP, PLGF 42/44 95 (85, 99) 118/190 62 (55, 69) 
MAP, SFLT 41/44 93 (81, 99) 112/190 59 (52, 66) 
UTPI, PLGF 39/44 89 (75, 96) 106/190 56 (48, 63) 
UTPI, SFLT 41/44 93 (81, 99) 98/190 52 (44, 59) 
PLGF, SFLT 44/44 100 (92, 100) 118/190 62 (55, 69) 
MAP, UTPI, PLGF 42/44 95 (85, 99) 118/190 62 (55, 69) 
MAP, UTPI, SFLT 43/44 98 (88, 99) 115/190 61 (53, 68) 
MAP, PLGF, SFLT 43/44 98 (88, 99) 124/190 65 (58, 72) 
UTPI, PLGF, SFLT 43/44 98 (88, 99) 119/190 63 (55, 70) 
MAP, UTPI, PLGF, SFLT 43/44 98 (88, 99) 124/190 65 (58, 72) 
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Figure S1: Distribution of measurements of biomarkers without adjustment for maternal 
factors. The vertical red lines indicate the 95th or 5th percentile for the biomarkers and the 
vertical blue lines indicate the 90th or 10th percentiles. 
 
 
